INTRODUCTION
Adoptive cellular therapy with T cells engineered to express chimeric antigen receptors (CARs) combines the antigen specificity of a monoclonal antibody with potent T cell activation, proliferative potential, and cytotoxic function. CARs comprise an extracellular antigen-binding domain, most commonly a single-chain variable fragment (ScFv), combined with a transmembrane domain and one or more intracellular signaling domains. First-generation CARs typically had a single CD3-z intracellular signaling domain; they were shown to have poor persistence in vivo.
1 Second-generation and third-generation CARs were created by the addition of one or two costimulatory endodomains to the CD3-z motif to provide tailored signals with the aim of enhancing activation and survival. Current costimulatory endodomain candidates include CD27, CD28, 41BB, ICOS, and OX40. Though CD19-specific CAR-T cells have shown impressive responses in patients with B cell hematological malignancies, in some cases leading to complete remission of chemotherapy refractory disease, 2 evaluation of CAR-T cells in solid tumors has so far been less successful. 3 For example, a phase 1 trial using first-generation GD2-CAR-T cells in patients with neuroblastoma demonstrated some objective clinical responses. 4, 5 However, a follow-up study with third-generation CAR has shown no evidence of enhanced clinical efficacy despite markedly enhanced cytokine secretion and proliferation in vitro. 6 We speculate that the poor responses against solid tumors might be due to the immunosuppressive tumor microenvironment impairing T cell homing, cytotoxicity, and survival. Thus, alternative approaches, including the use of unconventional lymphocytes that might be naturally tumoricidal and capable of enhanced tumor trafficking, should be evaluated. 7 Gamma delta T (gdT) cells are particularly intriguing given their capacity to differentiate following activation into cells with professional antigen presentation function.
gdT cells comprise 1%-5% of circulating T cells but are the predominant lymphocyte at epithelial surfaces. 8 A meta-analysis of gene expression data from more than 18,000 cancers identified infiltration by gdT cells to be the most significant factor associated with favorable prognosis. 9 gdT cells are a heterogeneous population characterized by expression of Vg (2-5, 8, and 9) and Vd (1) (2) (3) (4) (5) (6) (7) (8) chains to form a heterodimeric gdT cell receptor (TCR). gdT cells of the Vg9Vd2 subtype are predominant in circulating peripheral blood and can be selectively expanded in vitro and in vivo to a clinically significant number with zoledronate (ZOL), an aminobisphosphonate drug used in clinical practice to treat osteoporosis and bony metastatic disease. 10 ZOL inhibits farnesyl pyrophosphate synthase, an enzyme in the mevalonate pathway of cholesterol biosynthesis. This leads to an accumulation of upstream metabolites including isopentenyl pyrophosphate, resulting in activation and proliferation. 11 Vg9Vd2 cells have endogenous cytotoxicity against various tumors; 12 following activation, they can acquire phenotypic characteristics of professional antigen-presenting cells (gd-APCs), including capacity for cross presentation of tumor-associated antigens. [13] [14] [15] [16] gdT cells of the Vd1 subtype are also of potential clinical interest due to their naturally more naive memory (T naive ) phenotype, 17 a reduced susceptibility to activation-induced cell death, 18 and their natural residency in tissues. We and others have shown that this subclass can be expanded from peripheral blood to clinically significant numbers using artificial APCs, 19, 20 T cell mitogens such concanavalin A (ConA), 21 or anti-CD3 antibody. 22 Previous studies have described the feasibility of viral transduction 23 or electroporation 20 of gdT cells with CARs. However, the relative functionality of engineered CAR + gdT cells compared with conventional adoptive CAR + T cell approaches has yet to be fully characterized, and large-scale manufacturing protocols for adoptive T cell transfer of CAR + gdT cells have yet to be developed. Here we describe, using a GD2 antigen model against a range of GD2-expressing cells, an approach for the transduction and expansion of CAR + gdT cells from peripheral blood to sufficient numbers for adoptive T cell transfer. We also demonstrate the acquisition of both CAR-dependent antigen-specific killing and antigen cross-presentation function.
RESULTS

ZOL and ConA Activation Result in Preferential Expansion of gdT Cells from Peripheral Blood
To evaluate a potential role of human peripheral blood gdT cells as vehicles for CARs, we first evaluated different activation methods to facilitate both transduction and expansion to sufficient numbers for adoptive transfer. CD3/CD28 antibodies and ZOL and ConA activation of peripheral blood mononuclear cells (PBMCs) from healthy donors all led, to varying degrees, to expansion of gdT cells, as well as alpha beta T (abT) cells. ConA and ZOL led to preferential gdT cell expansion ( Figures 1A-1D ). As expected, ZOL preferentially expanded the Vd2 subtype (more than 80% purity by day 13 postactivation) ( Figures 1C and 1F ). In contrast, ConA led to expansion of both Vd1 and Vd2 cells ( Figures 1D and 1G ), although most cultured cells remained ab T cells by day 13 despite significantly greater fold expansion of Vd1 and Vd2 cells compared to ab ( Figures  1D and 1G ). There was also a high degree of inter-donor variability of fold expansion following ConA stimulation, possibly reflecting different degrees of priming of blood gdT cells in different individuals. Nevertheless, ConA was identified as a possible method for expansion of the rarer Vd1 subset.
Bulk Populations of gdT Cells Are Efficiently Transduced with a GD2-Specific CAR and Demonstrate Antigen-Specific Cytotoxicity Bulk populations of CD3/CD28-, ZOL-, and ConA-activated cells were efficiently transduced with a second-generation CAR targeting GD2 and containing CD3-z and CD28 signaling domains (GD2-CAR). CD3/CD28-activated cells were transduced with gammaretroviral supernatant 48 hr after the initial activation as previously described. 4 ConA and ZOL-activated cells were transduced 5 days post-stimulation, which had been identified as the optimal time point for maximal transduction efficiency and proliferation (Figure S1 ). Transduction efficiency, as determined by flow cytometry (Figure 2A ), was greatest for CD3/CD28-activated ab T cells, (mean 61.57%) ( Figure 2B ), although there was marked variability in transduction efficiency between donors (n = 9). Transduction following ZOL activation was highest in Vd2 cells, which is unsurprising given that ab and Vd1 failed to expand in ZOL cultures ( Figure 2C ). Following ConA activation, there was no significant difference between transduction efficiency of different T cell subsets, with all showing 20%-40% transduced cells, somewhat lower than with CD3/CD28 stimulation ( Figure 2D ). Therefore, both ZOL and ConA stimulation are capable of stimulating and transducing gdT cells from peripheral blood.
51
Chromium ( 51 Cr) release assays were used to investigate whether gdT cells transduced with secondgeneration GD2-CAR exerted specific tumor cell lysis. gdT cells, in the absence of CAR, have been shown to kill a variety of tumors, [24] [25] [26] [27] [28] enhanced by addition of opsonizing antibody 19 or target sensitization with ZOL. 29 We have previously shown that artificial APC-expanded Vd1 cells are capable of antibody-independent killing of certain GD2 + neuroblastoma cell lines but that Vd2 gdT cells demonstrate a lesser degree of innate killing. 19 We initially evaluated the killing properties of bulk GD2-CAR-transduced T cell populations following ZOL and ConA stimulation, using GD2-expressing LAN1 neuroblastoma cells as targets. Efficient cytotoxicity of LAN1 targets was observed using either stimulation protocol ( Figures 2F and 2G) , and the level of killing by gd CAR-T cells at an effector-to-target (E:T) ratio of 10:1 was broadly equivalent to that observed with ab CAR-T cells transduced with the same receptor following CD3/CD28 stimulation ( Figure 2E ). There was relatively little innate background killing by mock-transduced gdT cell controls ( Figures 2F and 2G ) against this particular neuroblastoma cell line. The antigen-specific nature of the cytotoxicity was confirmed by demonstration of effective killing of SupT1 cells engineered to express GD2, while there was negligible killing of SupT1 transduced with irrelevant control antigen ( Figure S2 ). Figure 3C ). Therefore, GD2-CAR + Vd2 T cells expanded by ZOL and polyclonal GD2-CAR + gdT cells expanded by ConA are both capable of antigen-specific killing that is at least equivalent to those of conventionally activated GD2-CAR ab T cells, and Vd2 T cells are additionally capable of effective ADCC.
ConA-Expanded gd CAR-T Cells Have a Less Differentiated Phenotype and Relatively Low Expression of Exhaustion Markers
gdT cell differentiation into effector or memory cells has been described by Dieli et al. 30 Antibody staining for CD27 and (T CM ), effector memory (CD27 À /CD45RA À ) (T EM ), and terminally differentiated effector memory (CD27 À /CD45RA + ) (T TEMRA ). T CM has the highest proliferative potential and express lymph node homing receptors but has a relative lack of immediate effector function. T EM is highly cytotoxic but has lower proliferative capacity. 31 ab T cells showed a general shift from a predominantly T naive and T CM phenotype to the T CM /T EM phenotype at day 13 following activation with CD3/CD28 antibody ( Figures 4A-4D ). In contrast with ab T cells, a large number of NTD and transduced Vd1 cells (activated with ConA) maintained a CD27 + /CD45RA + naive phenotype, which was not affected by prolonged culture or transduction with GD2-CAR ( Figures 4C and 4D ). In contrast, Vd2 + cells following activation with ZOL adopted a predominantly T EM phenotype, with few naive or T CM cells left in culture in both the absence ( Figure 4C ) and the presence ( Figure 4D + , and Vd2 + ) ( Figure 5A ). Antigen-specific proliferation was also evaluated using ZOL-expanded Vd2 CAR-T cells that underwent FACS in which a mean of 2.5-fold expansion was observed over 3 days in CAR + T cells in the presence of LAN1, while there was no www.moleculartherapy.org significant increase in numbers in the absence of target and/or CAR ( Figure 5B ).
The natural tissue residency of most gdT cells, and the association of tumor infiltration by gdT cells with favorable prognosis, 9 led us to speculate that cells expanded and transduced from blood might have favorable migration toward tumor cells for adoptive cell therapy.
To explore the migratory capacity of CAR + gdT cells toward neuroblastoma cells, a 4-hr transwell migration assay was performed. We first evaluated background migration due to T cell motility in the absence of any cells in the lower chamber and found that between mean 5% and mean 12% of the total population traverse the wells, with no significant differences in migration properties of the CARtransduced and NTD cells ( Figure 5C ). The background values were calculated for each cell type and subtracted from migration in the presence of a tumor cell stimulus to identify stimulus-specific migration ( Figure 5D ). It was found that all CAR + cells had positive mean values for migration toward two neuroblastoma cell lines, and there were no significant differences among Vd1 + , Vd2 + and ab CAR-T cells ( Figure 5D ). Similarly, we showed for each of the subtypes that the presence of the CAR did not significantly affect migratory properties in vitro ( Figure 5E ). CAR + gdT cells also migrated toward supernatant from neuroblastoma cell lines (Figure 5E) , and supernatant taken from neuroblastoma neurosphere lines derived from primary patient tissue ( Figure S3 ). Hence, gd CAR-T cells expanded by ConA retain chemo-attraction toward 5 of 5 neuroblastoma models, consistent with a potential role for these cells in adoptive transfer immunotherapy for this disease. Cross presentation to MHC class I molecules is a hallmark of pAPCs. To test the ability of the expanded gd CAR-T cells to function as cross-presenting pAPCs, we used the model cancer testis antigen MART1. Responder ab T cells were labeled with CellTrace and transduced with a recombinant abTCR with high-affinity specificity for a known 10 amino acid MART1 peptide/HLA-A0201 complex. 34 CellTrace dilution was assessed within the MART1 abTCR (V-beta 12 [Vb12] chain)-positive and (Vb12 chain)-negative gate, distinguishing antigen-specific and non-specific proliferation, respectively ( Figures 6B and 6C ). Using as a source of antigen for cross presentation a 25-mer MART1 long peptide (L-MART1) containing the 10-mer sequence, antigen-specific proliferation can only be detected if there is endocytosis and intracellular processing by pAPCs.
To test the ability of expanded and transduced gd CAR + T cells to function as pAPCs, we used blood from HLA-A201 + donors as the source of both gd CAR + T cells, as well as the autologous MART1 TCR + responders. To exclude the possibility of minor populations of other APCs in the ZOL-expanded gd CAR + T cells contributing to antigen presentation, we performed FACS for the Vd2-CAR population to purity with stringent gating. MART1 short peptide (S-MART1) pulsing of the gd CAR + T cells led to robust proliferation only of the Vb12 + population. Long peptide pulsing also led to antigen-specific proliferation, but only in the presence of cross-presenting gd CAR-T cells ( Figure 6C ). As expected, given the requirement for intracellular processing, long peptide-specific proliferation was less robust than short peptide-pulsed cells. The ability to cross present was found in gd CAR-T cells from a range of donors ( Figure 6D ).
DISCUSSION
Engineering of CAR-T cell therapy requires a fine balance between maximizing efficacy of tumor killing and reducing treatmentrelated morbidity, including on-target, off-tumor effects. Successful treatment of solid tumors also depends on the ability of CAR-T cells to home to the tumor site, overcome the immunosuppressive tumor microenvironment, and persist long term. Conventional approaches use ab CAR-T cells, which have resulted in impressive clinical responses in leukemia but have yet to be translated to equivalent successes in solid cancers. We identified gd CAR-T cells as a potential novel approach due to their additional desirable functional properties. Specifically, gd CAR-T cells, as a first line of defense, are already primed for innate cytotoxicity; 8 have natural residence in the solid tumor microenvironment; 9 and have been shown following activation to acquire phenotype and properties of profession APCs. [13] [14] [15] [16] We therefore tested the hypothesis that following transduction with a CAR, gd CAR-T cell products would be obtained and that these would retain the innate anti-cancer properties, as well as acquiring additional antigen-specific cytotoxicity and proliferative response. As a first proof of concept, we have used a second-generation CD28z endodomain-containing CAR and GD2 as a target antigen suitable for many solid cancers, including neuroblastoma. While further optimization is necessary, the data demonstrate retention of the important gdT functions of antigen cross presentation to effector T cells and migration toward tumor cells while gaining additional antigen-specific cytotoxicity.
gd CAR-T cells were expanded from the PBMCs of healthy donors using three T cell stimulation methods: CD3/CD28 antibody, ZOL, and ConA, of which CD3/CD28 antibody and ZOL are already available in good manufacturing practice (GMP) form. ZOL ex vivo expansion of Vg9Vd2 cells for adoptive transfer was also previously described 35 and used in early clinical trials.
ConA expansion for clinical applications would require further development but is an attractive proposition because of its more polyclonal expansion of gdT cells, including the more naive Vd1 + subset, and an increased frequency of cells lacking PD1 and TIM3 expression compared with the other methods; in addition, Vd1 + cells have been shown to have enhanced tumor killing, tissue penetration, and resistance to activation-induced cell death compared with Vd2 + cells. 18, 36 Greater numbers of CAR + Vd1 + are potentially achievable through, for example, enrichment by cell separation techniques during production, as described by Almeida et al., 22 or culturing in the presence of IL-2 and IL-7, as previously described. 37 ConA expansion might be of particular interest in childhood cancers, because Vd1 + cells are known to predominate during fetal development and childhood but by adulthood, most gdT cells in peripheral blood are Vg9Vd2 cells. 38 
Vd1
+ and Vd2 + gdT cell subsets were successfully transduced with GD2-CAR using a gamma-retroviral vector following ZOL or
ConA stimulation with adequate transduction efficiency for adoptive transfer, albeit somewhat lower than that observed with CD3/CD28-activated cells. This difference is probably explainable by the gentler stimulus of ZOL or ConA and could be ameliorated by using methods of gene transfer less dependent on cell division, such as lentiviral transduction or electroporation.
We have previously shown that expanded Vd1 + cells retain innate killing of neuroblastoma cells, 19 while Vd2 + cells lose cytotoxicity during expansion. 16, 19 In the current study, the innate cytotoxicity of the expanded cells following CD56 depletion was negligible against neuroblastoma (Vd1 and Vd2) ( Figure 2 ) and low against SupT1 cells (Vd2) (Figure S2 ). Although further studies will be required to www.moleculartherapy.org determine how much innate killing activity is preserved in expanded and transduced cells, the important message of our study is that CARdependent cytotoxicity is equivalent to that seen with conventional CAR ab T cells. The gd CAR-T cells are capable of further expansion following a second stimulation augmented by the presence of the cognate antigen for the CAR. A second-generation GD2-CD28-CD3-z CAR was chosen for this study because of the capacity of CD28 CARs for rapid acute response. 39 Future studies might assess tumor necrosis factor (TNF) receptor superfamily CAR endodomains for their capacity for more sustained expansion. 32, 39, 40 Most significantly, we have shown for the first time that expanded and CAR-transduced gdT cells are capable of migrating toward tumor cells and of antigen cross presentation. This finding opens a new avenue of research, because it suggests that a CAR-T cellular product has the capacity to enter the tumor site, where it is responsible for both killing of tumor cells and release of tumor-associated antigens, as well as uptake of released antigens, leading to stimulatory antigen presentation to tumor-infiltrating lymphocytes. This approach is likely to be of interest in diseases like melanoma with high tumor antigen frequency and large numbers of tumor-reactive, tumor-infiltrating lymphocytes. We conclude that gd CAR-T cells can be generated in sufficient number for adoptive transfer immunotherapy for cancer and have potent tumor antigen-dependent cytotoxicity. Their capacity for migration and for uptake and cross presentation of tumor-associated antigens marks them as having potential advantages over conventional CAR-T cells, especially in the solid tumor setting.
MATERIALS AND METHODS
Cell Lines and Primary Cells
Human neuroblastoma cell lines LAN1 and SK-N-SH and a lymphoblastic lymphoma cell line (SupT1) were obtained from the ATCC. Fresh blood samples were obtained from healthy laboratory donors in accordance with protocols approved by the UK Integrated Research Ethics Review, after obtaining informed consent.
Activation and Expansion of T Cells
PBMCs were isolated from whole blood by density gradient centrifugation (Lymphoprep, Stem Cell Technologies, Cambridge, UK). Two methods for gdT cell expansion were employed. First, for selective expansion of the Vg9Vd2 subtype (Vd2 + ), PBMCs were resuspended in medium (RPMI, 10% fetal calf serum [FCS] , 1% penicillin/streptomycin [PS]) supplemented with 100 IU/mL IL-2 (Proleukin, Prometheus, Switzerland) and 1 mg/mL ZOL (Zerlinda at 4 mg/100 mL, Actavis). Second, for the expansion of polyclonal gdT cells, including those bearing the Vd1 + and Vd2 + TCR, PBMCs were resuspended in medium (RPMI, 10% FCS, 1% PS) supplemented with 100 IU/mL IL-2, 10 ng/mL recombinant IL-4 (Cellgenix), and 1 mg/mL ConA (Sigma-Aldrich). ab T cells were activated and expanded using 1 mg/mL soluble anti-CD3 (clone OKT3, Miltenyi) and anti-CD28 antibodies (clone 15E8, Miltenyi) (CD3/CD28). All cell cultures were incubated at 37 C and 5% CO 2 and maintained at a cell density of 1 Â 10 6 /mL. Fresh media containing 100 IU/mL IL-2 (and 10 ng/mL IL-4 for ConA-activated cells) was replenished every 2-3 days.
CAR
The clinical-grade retroviral vector SFGmR.RQR8-2A-aGD2-huK666-HCH2CH3pvaa-CD28Z (referred to as GD2-CAR hereafter) was used for all studies. The construct includes two transgenes: a second-generation CAR comprising the ScFv from murine anti-GD2 antibody (muK666), 41 which has subsequently been codon optimized and humanized to form huK666. 42 huK666 is fused with an immunoglobulin G (IgG) Fc spacer, a CD28 transmembrane domain, and the CD28 and CD3-z intracellular signaling domains. The marker/suicide gene, RQR8, is coexpressed with the CAR using a foot and mouth virus, self-cleaving 2A sequence as previously described. 43 Coexpression of RQR8 allows elimination of CAR + T cells by anti-CD20 monoclonal antibody (Rituximab) should toxicities occur, and the target epitope from CD34, which is targeted by the anti-CD34 clone QBend10, allows detection of transduced GD2-CAR + cells by flow cytometry.
Production of Retroviral Supernatant and Transduction of T Cells
High-titer retroviral supernatant pseudotyped with the RD114 envelope was generated by incubating infected HEK293 cells for 48 hr in culture medium (90% DMEM, 10% FCS, 4 mM L-glutamine, 1% PS) at 37 C and 5% CO 2 . Following incubation, supernatants were frozen and stored at À80 C until further use.
For production of gd CAR + T cells, PBMCs stimulated with ZOL (+IL-2 at 100 IU/mL) or ConA (+IL-2 at 100 IU/mL and IL-4 at 10 ng/mL) were transduced in 24-well plates pre-coated with recombinant fibronectin fragment (RetroNectin, Takara, Japan), 5 days following initial activation. 48 hr after transduction, gd CAR-T cells were expanded with IL-2 (100 IU/mL) added every 2-3 days. For ab T cell control experiments, CD3/CD28 antibody-stimulated PBMCs were transduced 48 hr following the initial activation and thereafter treated according to the same protocol as for gd CAR-T cells.
Flow Cytometry
All flow cytometry data were acquired on BD LSRII flow cytometer, and results were analyzed using FlowJo software (v.X.0.7, Tree Star, Ashland, OR). Compensation was carried out using single-color controls of either cells or beads (OneComp eBeads, eBioscience 
Cytotoxicity Assays
In vitro cytotoxicity was assessed using standard 4-hr 51 Cr release assay as previously described. 19 Expanded transduced and NTD gd and ab cells were used as effectors, and human neuroblastoma LAN1 cells were used as targets. LAN1 cells were labeled with 100 mCi Na 2 51 CrO 4 and cocultured with effector cells at a range of E:T ratios. Human IgG1 anti-GD2 antibody (Ch14.18/CHO) was used to opsonize GD2 + LAN1 cells before labeling where stated.
Secondary Re-expansion Day 14 ConA-expanded effector cells were cocultured with irradiated (80 Gy) LAN1 cells at a 1:1 ratio for 7 days. 1 Â 10 6 effectors and 1 Â 10 6 LAN1 were cocultured in 24-well plates in the presence of IL-2 (100 IU/mL). Cell density was maintained at 1 Â 10 6 cells/mL, and fresh media and IL-2 were replenished every 2-3 days. After 7 days, cells were harvested and counted using trypan blue exclusion. Specific T cell subset expansion within bulk effector cultures was determined by staining for Vd1 + , Vd2 + , anti-TCR gd, anti-TCR ab, cells were seeded in the upper wells, and lower wells contained (1) 600 mL of supernatant of confluent LAN1 or SK-N-SH cultures, (2) 600 mL of supernatant of neuroblastoma primary cell cultures, or (3) LAN1 or SK-N-SH overnight cultures of 0.5 Â 10 6 tumor cells. RPMI + 10% FCS in the lower compartment served as a negative control, representing the random background migration of immune cells, and by transferring all cells (0.5 Â 10 6 ) to the lower well, we determined the maximum possible yield (positive control). As an assay control, we included the condition whereby the lower well contained 100 ng/mL SDF-1 (CXCL12, Sigma-Aldrich). Cell migration was allowed for 4 hr at 37 C and 5% CO 2 , whereupon migrated cells were collected from the lower compartment. Counting beads (Precision Count Beads, BioLegend) were added, and then cells were resuspended in a fixed volume and counted flow cytometrically. Migration was expressed using the following equation: percentage of migration = (number of migrated cells in the specific condition À number of migrated cells in the negative control) / number of migrated cells in the positive control) Â 100. We gated on both the CAR + and the NTD of each subtype within the bulk migrated population to determine whether the presence of the CAR influenced migration.
Tumor Antigen Cross-Presentation Assays ZOL-activated, CAR-transduced Vd2 + T cells were cultured for 13 days in the presence of 100 IU IL-2 before stringent purification by FACS. After 24 hr, purified CAR + Vd2 + T cells were pulsed with cancer testis antigen MART1-short peptide (MART1 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , ELAGI GILTV), long peptide (MART1 , GHGHSYTTAEELAGIGILT VILGVL) (ProteoGenix, France), or no peptide-for 4 hr at 37 C in serum-free medium. All peptides were used at a concentration of 5 m/mL. Cells were then washed twice before coculture with responder ab T cells.
Specific MART1 TCR
+ ab T cells were produced from frozen autologous PBMCs taken from the same blood draw as that used for the Vd2 + T cell expansion. PBMCs were thawed on day 5 and activated with 1 mg/mL CD3, 1 mg/mL CD28 antibody, and 100 IU IL-2. 48 hr later, cells were transduced on RetroNectin-coated, 24-well plates with viral supernatant containing a recombinant abTCR with high-affinity specificity for a known 10 amino acid MART1 peptide/HLA-A0201 complex 34 (MART1-TCR) using the identical protocol described earlier for the preparation of GD2-CAR ab T cells.
MART1 abTCR viral supernatant was produced by transient cotransfection of HEK293T cells with RD114 envelope protein, gag-pol, and plasmid-encoding MART1-TCR (gift from C. Cohen). In brief, 1.5 Â 10 6 HEK293T cells were cultured in DMEM/10% FCS in a 100-mm dish (Nunclon Delta Surface, Thermo Fisher) for 24 hr before cotransfection using GeneJuice Transfection Reagent (Novagen/Millipore, Massachusetts, USA) according to manufacturer instructions. 
